PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $13,810 | -99.9% | 500,000 | -37.5% | 0.43% | -46.0% |
| Q1 2022 | $18,946,000 | -55.7% | 800,100 | -36.0% | 0.79% | -31.6% |
| Q4 2021 | $42,750,000 | +60.8% | 1,250,000 | -16.7% | 1.16% | +95.0% |
| Q3 2021 | $26,580,000 | +1268.0% | 1,500,000 | +1900.0% | 0.60% | +1650.0% |
| Q1 2021 | $1,943,000 | -27.5% | 75,000 | -43.6% | 0.03% | -41.4% |
| Q4 2020 | $2,681,000 | +3.1% | 133,000 | 0.0% | 0.06% | -7.9% |
| Q3 2020 | $2,600,000 | +5.2% | 133,000 | -5.0% | 0.06% | -8.7% |
| Q2 2020 | $2,472,000 | – | 140,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |